findmyKOL
Clinical trialNCT06760156RecruitingPhase 2Interventional

Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym

SponsorH. Lee Moffitt Cancer Center and Research InstituteEnrollment28Large B-cell Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of the study is to evaluate the safety and efficacy of tafasitamab and lenalidomide in participants with Large B Cell Lymphoma (LBCL) after axicabtagene ciloleucel (axi-cel) treatment. Participants will be asked to spend about 12 months in this study.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Moffitt Cancer Center

    Tampa, Florida, United States

    Aleksandr Lazaryan, MD, PhDBijal Shah, MDFarhad Khimani, MDFrederick Locke, MD →Julio Chavez, MDMichael Jain, MD, PhDSameh Gaballa, MDSayeef Mirza, MDTaiga Nishihori, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Lenalidomide →Tafasitamab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
19 Mar 2025
Primary completion
31 Jan 2027
Completion
31 Jan 2028
Last update posted
3 Apr 2026
Registered enrollment
28
Registry id
NCT06760156
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.